CLOUDBREAK-B (02592.HK): SFC suspends share trading amid investigation into suspected IPO manipulation

NewTimeSpace News: On 10 September 2026, the Securities and Futures Commission (SFC) announced that it has, under section 8(1) of the Securities and Futures (Stock Market Listing) Rules, directed The Stock Exchange of Hong Kong Limited to suspend trading in the shares of Cloudbreak Pharma Inc. (stock code: 02592) with effect from 9:00 a.m. on 10 September 2026.

The SFC said it has serious concerns that the initial public offering of Cloudbreak Pharma may have been artificially manipulated to create a false appearance of demand for its shares. The SFC therefore considers it necessary or appropriate to suspend trading in the shares pending the ongoing investigation, in order to maintain an orderly and fair market for the shares and to protect the interests of the investing public. As the investigation is ongoing, the SFC will not comment further.

Under section 8(1) of the Securities and Futures (Stock Market Listing) Rules, the SFC may direct the Stock Exchange to suspend trading in the shares of a listed company where any document issued in connection with the listing of securities, or any announcement, statement, circular or other document made or issued by or on behalf of the listed company, contains information that is false, incomplete or misleading in a material particular; where suspension is necessary or appropriate to maintain an orderly and fair market; where suspension is appropriate in the interests of the investing public or the public interest; or where any condition imposed by the SFC board under section 9(3)(c) upon approving the resumption of trading has not been complied with. Cloudbreak Pharma has been listed on the Main Board of the Stock Exchange since 3 July 2025, and the investigation is conducted under section 182(1) of the Securities and Futures Ordinance.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.